Alnylam Pharmaceuticals ALNY announced preliminary net product revenues for the fourth quarter and full-year 2024 for its ...

A new study from Karolinska Institutet and Mayo Clinic has revealed important insights into brain degeneration in dementia ...

The Florey Dementia Index (FDI) is valid for predicting the age of onset of mild cognitive impairment (MCI) and Alzhei ...

Groundbreaking research reveals potential link between cytomegalovirus (CMV) and Alzheimer's disease, offering new insights ...

Having depression is known to increase a person’s risk of developing dementia, but depression is also an early indicator of ...

Johnson & Johnson will spend more than $14 billion to move deeper into treating central nervous system disorders by ...

Mild chronic small vessel disease, or cerebral small vessel disease (CSVD), is an umbrella term for a range of conditions ...

The Phase Ia trial is designed to assess the company’s drug designed to target chemicals thought to be a cause of Alzheimer’s disease.

Gum disease appears to disrupt brain activity, potentially increasing a person’s risk of cognitive decline.People with ...

IGC Pharma, Inc (NYSE American:IGC) (”IGC” or the “Company”), today announced that CEO Ram Mukunda and CCO Claudia Grimaldi ...

Johnson & Johnson (NYSE: JNJ) and Intra-Cellular Therapies, Inc. (Nasdaq: ITCI) announced today that they have entered into a definitive agreement under which Johnson & Johnson will acquire all ...

Delray Medical Center cut the ribbon on its newest high-tech machine that targets brain areas to treat movement disorders ...